Immunogenicity and safety of hepatitis e vaccine in healthy hepatitis B surface antigen positive adults

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 11, 2013, Pages 2474-2479

  Wu, Ting ^a   Huang, Shou Jie ^a   Zhu, Feng Cai ^b   Zhang, Xue Feng ^b   Ai, Xing ^b,e   Yan, Qiang ^a   Wang, Zhong Ze ^c   Yang, Chang Lin ^c   Jiang, Han Min ^c   Liu, Xiao Hui ^d   Guo, Meng ^d   Du, Hai Lian ^a   Ng, Mun Hon ^a   Zhang, Jun ^a   Xia, Ning Shao ^a  

^a XIAMEN UNIVERSITY   (China)

^b JIANGSU PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c Dongtai Center for Disease Control and Prevention   (China)

^d Xiamen Innovax Biotech   (China)

^e CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

HBsAg; Hecolin ; Hepatitis E; HEV239; Immunogenicity; Safety; Vaccine

Indexed keywords

HECOLIN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS E VACCINE; IMMUNOGLOBULIN G; PLACEBO; UNCLASSIFIED DRUG; HEPATITIS VACCINE; RECOMBINANT VACCINE; VIRUS ANTIBODY;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; CLINICAL PROTOCOL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPATITIS E; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; MALE; NORMAL HUMAN; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; UNSPECIFIED SIDE EFFECT; AGED; BLOOD; COMPLICATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEPATITIS B; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, VIRAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS E; HUMANS; MALE; MIDDLE AGED; VACCINES, SYNTHETIC; VIRAL HEPATITIS VACCINES; YOUNG ADULT;

EID: 84887490349     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.25814     Document Type: Article

References (24)

1. Kamar N, Bendall R, Legrand-Abravanel F, Xia NS, Ijaz S, Izopet J, et al. Hepatitis E. Lancet 2012; 379: 2477-88; PMID: 22549046; http://dx.doi.org/10. 1016/S0140-6736(11)61849-7
2. Purcell RH, Emerson SU. Prevention. In: Thomas HC, Lemon S, Zuckerman AJ, eds. Viral hepatitis, 3rd edn. Malden, MA Blackwell Publishing; 2005: 635-45.
3. Dalton HR, Stableforth W, Thurairajah P, Hazeldine S, Remnarace R, Usama W, et al. Autochthonous hepatitis E in Southwest England: natural history, complications and seasonal variation, and hepatitis E virus IgG seroprevalence in blood donors, the elderly and patients with chronic liver disease. Eur J Gastroenterol Hepatol 2008; 20: 784-90; PMID: 18617784; http://dx.doi.org/10. 1097/MEG.0b013e3282f5195a
4. Mizuo H, Yazaki Y, Sugawara K, Tsuda F, Takahashi M, Nishizawa T, et al. Possible risk factors for the transmission of hepatitis E virus and for the severe form of hepatitis E acquired locally in Hokkaido, Japan. J Med Virol 2005; 76: 341-9; PMID: 15 9 0 2 7 0 1; http://dx.doi.org/10.1002/jmv.20364 (Pubitemid 40770889)
5. Mansuy JM, Peron JM, Abravanel F, Poirson H, Dubois M, Miedouge M, et al. Hepatitis E in the south west of France in individuals who have never visited an endemic area. J Med Virol 2004; 74: 419-24; PMID: 153 6 8 5 0 8; http://dx.doi.org/10.1002/jmv.20206 (Pubitemid 39281640)
6. Tsang TH, Denison EK, Williams H V, Venczel LV, Ginsberg MM, Vugia DJ. Acute hepatitis E infection acquired in California. Clin Infect Dis 2000; 30: 618-9; PMID: 10722465; http://dx.doi.org/10.1086/313730 (Pubitemid 30205326)
7. Dalton HR, Fellows HJ, Gane EJ, Wong P, Gerred S, Schroeder B, et al. Hepatitis E in new zealand. J Gastroenterol Hepatol 2007; 22: 1236-40; PMID: 17489963; http://dx.doi. o r g/10.1111/j.14 4 0-174 6. 2 0 0 7. 0 4 8 9 4. x (Pubitemid 47222654)
8. Dalton HR, Hazeldine S, Banks M, Ijaz S, Bendall R. Locally acquired hepatitis E in chronic liver disease. Lancet 2007; 369: 1260; PMID: 17434 40 0; http://dx.doi.org/10.1016/S0140-6736(07)60595-9 (Pubitemid 46566523)
9. Péron JM, Bureau C, Poirson H, Mansuy JM, Alric L, Selves J, et al. Fulminant liver failure from acute autochthonous hepatitis E in France: description of seven patients with acute hepatitis E and encephalopathy. J Viral Hepat 2007; 14: 298-303; PMID: 17439518; http://dx.doi. o r g/10.1111/j.13 65-2 893. 2 0 07. 0 0 85 8. x (Pubitemid 46587857)
10. Kumar Acharya S, Kumar Sharma P, Singh R, Kumar Mohanty S, Madan K, Kumar Jha J, et al. Hepatitis E virus (HEV) infection in patients with cirrhosis is associated with rapid decompensation and death. J Hepatol 2007; 46: 387-94; PMID: 17125878; http://dx.doi.org/10.1016/j.jhep.2006.09.016 (Pubitemid 46185699)
11. Ramachandran J, Eapen CE, Kang G, Abraham P, Hubert DD, Kurian G, et al. Hepatitis E superin-fection produces severe decompensation in patients with chronic liver disease. J Gastroenterol Hepatol 20 04; 19: 134-8; PMID: 14731121; http://dx.doi.org/10.1111/j.144 0-174 6.20 04.0318 8.x (Pubitemid 38253351)
12. Zhu FC, Zhang J, Zhang XF, Zhou C, Wang ZZ, Huang SJ, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 2010; 376: 895-902; PMID: 20728932; http://dx.doi.org/10.1016/S0140-6736(10)61030-6
13. Park SB. Hepatitis E vaccine debuts. Nature 2012; 491: 21-2; PMID: 23128204; http://dx.doi.org/10.1038/491021a
14. Kumar M, Herrera JL. Importance of hepatitis vaccination in patients with chronic liver disease. South Med J 2010; 103: 1223-31; PMID: 21057383; http://dx.doi.org/10.1097/SMJ.0b013e3181fae4e8
15. Wu JC, Chen CL, Hou MC, Chen TZ, Lee SD, Lo KJ. Multiple viral infection as the most common cause of fulminant and subfulminant viral hepatitis in an area endemic for hepatitis B: application and limitations of the polymerase chain reaction. Hepatology 1994; 19: 836-40; PMID: 8138254; http://dx.doi.org/ 10.1002/hep.1840190406
16. Wang JY, Lee SD, Tsai YT, Lo KJ, Chiang BN. Fulminant hepatitis A in chronic HBV carrier. Dig Dis Sci 1986; 31: 109-11; PMID: 3940818; http://dx.doi.org/10.1007/BF01347921
17. Lee SD, Chan CY, Yu MI, Lu RH, Chang FY, Lo KJ. Hepatitis B vaccination in patients with chronic hepatitis C. J Med Virol 1999; 59: 463-8; PMID: 10534727; http://dx.doi.org/10.1002/(SICI)1096-9 071(199912 )59: 4 3.0.CO;2-5
18. Keeffe EB, Iwarson S, McMahon BJ, Lindsay KL, Koff RS, Manns M, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 1998; 27: 881-6; PMID: 9500723; http://dx.doi.org/10.1002/ hep.510270336 (Pubitemid 28103570)
19. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2; PMID: 19714720; http://dx.doi.org/10.1002/hep.23190
20. Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-71; PMID: 15 0 5 7 9 2 0; http://dx.doi.org/10.1002/ hep.20119 (Pubitemid 38428955)
21. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 20 02; 19: 1-46; PMID: 14768714
22. Jacobs RJ, Meyerhoff AS, Saab S. Immunization needs of chronic liver disease patients seen in primary care versus specialist settings. Dig Dis Sci 2 0 0 5; 5 0: 152 5-31; PMID: 16110 8 47; http://dx.doi.org/10.1007/s10620-005- 2873-5 (Pubitemid 41039204)
23. Arguedas MR, Fallon MB. Prevention in liver disease. Am J Med Sci 2001; 321: 145-51; PMID: 11217817; http://dx.doi.org/10.1097/00000441-200102000-00006 (Pubitemid 32128793)
24. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48: 335-52; PMID: 18096267; http://dx.doi. o r g/10.1016/j.j h e p. 2 0 0 7.11.011